Erdheim-Chester's disease (ECD) pathophysiology remains largely unknown. Its treatment is not codified and usually disappointing. Interferon-α (IFN-α) therapy lacks efficacy for some life-threatening manifestations and has a poor tolerance profile. Because IL1Ra synthesis is naturally induced after stimulation by IFN-α, we hypothesized that recombinant IL1Ra (anakinra) might have some efficacy in ECD. We treated 2 patients who had poor tolerance or contraindication to IFN-α with anakinra as a rescue therapy and measured their serum Creactive protein (CRP), interleukin-(IL)-1β, IL-6, and monocytic membranous IL-1α (mIL-1α) levels prior, under and after therapy. Another untreated ECD patient and 5 healthy subjects were taken as controls. After treatment, fever and bone pains rapidly disappeared in both patients, as well as eyelid involvement in one patient. In addition retroperitoneal fibrosis completely or partially regressed and CRP, IL-6 and mIL-1α levels decreased to within the normal and controls range. Beside injection site reactions, no adverse event was reported. Therefore, our results support a central role of the IL1 network, which appeared to be overstimulated in ECD. Its specific blockade using anakinra thereby opens new pathophysiology and therapeutic perspectives in ECD.
Introduction
Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis (approximately 350 worldwide described cases) characterized by tissue infiltration with lipoid granulomas composed of foamy CD68-positive but CD1a-negative macrophages, in contrast to Langerhans cells. These macrophages are also usually negative for the S-100 protein.
1,2 Its classification as a tumoral or inflammatory disease remains controversial, and its etiology and pathophysiological mechanisms are poorly understood, even though several studies have demonstrated a role of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. 3, 4 Clinical features range from indolent and isolated bone involvement to more systemic and potentially life-threatening forms. Patients more typically present with symmetrical sclerosis of the diaphysometaphyseal regions of the long bones, but the involvement of other bones and pseudo-infarction or lytic osseous lesions have also been described. Extraskeletal manifestations include pituitary gland and retroperitoneal or periureteral infiltrations, potentially leading to diabetes insipidus or hydronephrosis, respectively. Constitutional symptoms, like hectic fever, are frequent. The prognosis of ECD is poor; 59% of patients die after a mean follow-up of 32 months. 2 Several therapeutic approaches have been tested, including corticosteroids, bisphosphonates, and cytotoxic drugs, which are sometimes followed by autologous hematopoietic stem-cell transplantation, but only as case reports or in small series. Results are variable, often with incomplete and/or transient responses and frequent toxicity. 3, 5, 6 More recently, interferon-alpha (IFN-α) therapy has been suggested as a valuable first-line treatment with variable efficacy and a limited tolerance profile. Moreover, cardiovascular and central nervous system involvements do not seem to be responsive. [7] [8] [9] [10] The IL-1 receptor antagonist (IL1Ra) is the natural negative regulator of IL-1, acting via competitive binding to its membranous receptor with resulting anti-inflammatory effects.
For personal use only. on September 14, 2017 . by guest www.bloodjournal.org From Subcutaneous administration of IFN-α or IFN-β increases both molecular transcription and the secretion of IL1Ra [11] [12] [13] [14] [15] , suggesting that IFN-α therapy might indeed act, at least in part, through modulation of the IL-1 pathway. Therapy with the recombinant form of IL1Ra
(anakinra) has been reported to be effective and safe in several auto-inflammatory diseases, such as cold auto-inflammatory periodic fevers and familial Mediterranean fever, in which IL-1 has a pivotal role. [16] [17] [18] [19] [20] We successfully treated 2 ECD patients with anakinra because of a contra-indication, an incomplete response, or a poor tolerance to IFN-α therapy. We measured some proinflammatory cytokines levels prior to, during and after anakinra therapy, as well as in another ECD patient who did not receive anakinra and 5 healthy controls, to further support our hypothesis regarding the pivotal role, and effective and save therapeutic target of IL1 in
ECD.
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Methods

Patients and controls
Two ECD patients with intractable disease and intolerance or contraindication to IFN-α were treated with anakinra as a salvage treatment. ECD diagnosis relied on compatible clinical and radiological presentations and was histologically proven. Patient 1 had a 15 year history of psychosis, including chronic depression with 6 suicide attempts and dissociation, and had received antipsychotic and antidepressant drugs. IFN-α therapy was thereby contraindicated and she failed to respond permanently to cladribine. Patient 2 had an incomplete response to IFN-α therapy with retroperitoneal involvement and renovascular hypertension; he suffered an IFN-α-related flu-like syndrome and depression, leading to withdrawal. Both patients as well as their families refused combined cytotoxic regimens. Before starting anakinra, patients received information on its potential benefit and toxicity, and they signed consent forms. A third ECD patient was taken as a control. He had stabilized disease with limited bilateral tibial involvement and received no specific treatment. Table I summarizes the main disease characteristics and treatments of these 3 patients.
Five healthy adults (blood donors) were taken as controls for peripheral blood mononuclear cell (PBMC) isolation and flow cytometry analyses.
Approval for this study was obtained from the "Comité de Protection des Personnes-Ile de 
Serum cytokines and C-reactive protein measurements
Serum levels of IL-1β, IL-2, IL-6, IL-10, tumor necrosis factor (TNF)-α and IFN-γ were assessed for all three ECD patients using enzyme linked immunosorbent assay (ELISA) tests (BioSource Europe, Belgium). Measurements were made on frozen serum samples obtained prior to and/or after anakinra treatment from the 2 ECD anakinra recipients and on fresh serum samples from controls and the untreated ECD patient. C-reactive protein (CRP; normal < 5 mg/L) levels were measured at serial intervals.
Peripheral blood mononuclear cells isolation and flow cytometry
PBMCs were isolated by Ficoll-Paque from whole blood samples taken before anakinra 99 Technicium scintigraphy showed a complete disappearance of the previously observed sites of increased uptakes, which had slightly persisted after cladribine treatment, but X-ray lesions on the leg bones remained unaltered. Kidney function returned to normal, and Patient 1 stopped anakinra at month 11 on her own initiative because she felt improvement. She subsequently suffered a fever after 10 days off treatment; anakinra restart was allowed, and the patient again had a rapid and complete disappearance of fever. She remained well, and ureteral stents were withdrawn at month 18. She eventually decided on her own to stop the treatment at month 25. At month 32, she started to suffer recurrent mild and intermittent leg pains that were well controlled with paracetamol but had no fever spikes.
Treatment with anakinra was reinstituted at month 36 with the same response.
Patient 2 had a similarly good response with urological involvement, leading to the withdrawal of the left ureteral stent. Uretero-pyelography performed 10 months after anakinra onset found that the stenosis had totally subsided, but that some abnormalities persisted, including slight residual segmental ureteral hypotonia and dilatation. Conversely, no radiological improvement was noticed on skeletal scintigraphy, and the periaortic infiltrate shown in Figure 1 , panels C and D, remained unchanged at months 8 and 11, respectively. On this basis, treatment with anakinra was continued, with 26 months of follow-up from its onset.
CRP measurements
Both treated ECD patients exhibited a dramatic decrease and normalization of previously Under treatment with anakinra, cytokines levels were performed only for Patient 1 (Table II) .
Only IL-6 levels appeared to parallel the CRP decrease in Patient 1. Indeed, CRP and IL-6 levels were highest before treatment with anakinra and then decreased at the same time to normal values during treatment. TNFα values were increased during both prior and ongoing anakinra treatment periods, and reached the normal value only at the last measurement under treatment. IL-1β levels ranged between normal and high values for both prior and during treatment periods.
IL1α expression on peripheral monocytes
Active and untreated ECD patients had a high expression of IL1α on monocytes cell surface ( Figure 2A, 2B and 2C ).
For 
Discussion
Whereas the pathophysiological mechanisms involved in ECD are largely unknown, our results support the use of anakinra to treat ECD patients and, therefore, our hypothesis on the pivotal role of the IL-1 pathway in ECD. Our 2 ECD patients treated with anakinra indeed achieved both clinically and biologically complete or good responses, notably for constitutional symptoms and fever, as soon as 24 hours to a few days after the first injection.
A response was also observed in retroperitoneal fibrosis; although this response was not complete for one of the patients, it allowed for the removal of ureteral stents in both patients.
While the use of IFN-α therapy in ECD was based on its multifunctional, redundant and pleiotropic activities for regulating the immune system and responses, 7, 8 
IL1Ra
. 24, 25 IL-1α and IL-1β both play a leading role in the inflammatory process as the most pyrogenic fever-inducing cytokines besides their downstream IL-6 cytokine, 26 leading to the increase of CRP level. IL-1α is expressed at the membrane surface after cell stimulation and acts through autocrine and juxtacrine (i.e., intercellular contacts) actions. 17 In contrast, IL-1β is a circulating protein with paracrine actions, for which activation is controlled by the socalled "inflammasome complex". Anakinra was shown to be effective in several autoinflammatory systemic diseases, including cryopyrin-associated periodic syndrome (CAPS), [17] [18] [19] [20] 27 in which the "IL-1β inflammasome" function is abnormally increased because of a NLRP3 receptor gene mutation within monocytes, leading to a greater amount of circulating IL-1β. 16, 17, [28] [29] [30] Although anakinra was effective, we did not observe any significant increase of IL-1β levels in our patients. Hence, the efficacy of anakinra could also Other mechanisms might be implicated in ECD, such as a decreased production or impaired function of IL1Ra. [31] [32] [33] Two research groups recently described an autoinflammatory disease related to an IL1Ra gene mutation named DIRA because of the deficit of IL1Ra 34, 35 . This last phenomenon indeed shares peculiar fibrosclerosing and lytic bone
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From lesions and exhibits similar outcomes under therapeutics, i.e., no significant improvement with corticosteroids but a dramatic response with anakinra. 2, 7, 36 The response to anakinra on ECD might be variable according to the organ(s) involved, as already reported with IFN-α, which appears to be slowly effective on bone lesions and diabetes insipidus and almost ineffective on cardiac, aortic, central nervous system 8, 10 , pulmonary and sometimes mesenteric involvement. 9 However, because ECD is a very rare disease, the largest assessment of IFN-α is a retrospective study on only 8 patients. injection. Anakinra since exhibits a good tolerability and safety profile, as assessed by large previous studies in rheumatoid arthritis patients 40, 41 and in our two patients. Because of its specific targeting properties, anakinra should become an interesting alternative to IFN-α therapy, which is often hampered by dose-limiting side effects. 42, 43 In addition IFN-α therapy might be less efficient in patients receiving immunosuppressants or corticosteroids that are usually ineffective for treating ECD and that impaired the endogenous production of IL1Ra.
In conclusion, our results suggest that anakinra represents a potentially safe and effective treatment of ECD. Moreover, our results shed new light on the pathophysiology and
For personal use only. on September 14, 2017. by guest www.bloodjournal.org From therapeutic strategy of ECD by demonstrating the central role of IL-1 network, which appeared to be overstimulated in ECD like in auto-inflammatory processes. However, a larger multicenter prospective study is warranted to confirm our findings and to assess precisely the role and the best use of anakinra or other IL-1 blockers in ECD.
